🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Combination Treatment of PDS0101 and Pembrolizumab

    PDS Biotechnology Corp

    Recurrent Head and Neck Cancer

    phase 3 other active

    1 trial

  2. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  3. Conceptrol

    Evofem Biosciences

    Contraception

    phase 3 small molecule completed

    1 trial

  4. Copiktra 25 mg hard capsules, Copiktra 15 mg hard capsules, DUVELISIB , BENDAMUSTINE , GEMCITABINE

    Secura Bio Limited

    relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype

    phase 3 small molecule active

    1 trial

  5. Counseling + Transfer

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Addiction

    phase 3 small molecule completed

    1 trial

  6. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  7. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  8. DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  9. DACARBAZINE, PEMBROLIZUMAB, IDE196 (LXS196), CRIZOTINIB, IPILIMUMAB, NIVOLUMAB, CRIZOTINIB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  10. Darovasertib

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  11. Deferiprone oral solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule completed

    1 trial

  12. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  13. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Glioblastoma Multiforme

    phase 3 small molecule active

    1 trial

  14. Denifanstat

    Sagimet Biosciences

    MASH

    phase 3 small molecule terminated

    1 trial

  15. Depot naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  16. Descovy or Truvada

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  17. Diacomit 250 mg hard capsules, Matched Placebo will consist in caspules similar to the 250 and 500 mg capsules of stiripentol but with no active ingredient, Diacomit 500 mg hard capsules

    Biocodex

    Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)

    phase 3 small molecule active

    1 trial

  18. Directly administered antiretroviral therapy (DAART)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    2 trials

  19. Divalproex Sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit and Disruptive Behavior Disorders

    phase 3 small molecule completed

    1 trial

  20. Domvanalimab

    Arcus Biosciences

    Advanced Upper Gastrointestinal Tract Adenocarcinoma

    phase 3 small molecule active

    1 trial

  21. Double encapsulated oral transplant of fecal microbiota, Enema transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota, Placebo coloscopic transplant of Fecal microbiota

    Pari Pharma GmbH

    Primary Sclerosing Cholangitis

    phase 3 small molecule active

    1 trial

  22. Double encapsulated oral transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Severe Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  23. Drisapersen

    BioMarin Pharmaceutical Australia Pty Ltd

    Muscular Dystrophies

    phase 3 small molecule terminated

    2 trials

  24. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources